Sontag Family Trust

Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company specializes in harnessing molecular machines that convert energy into mechanical work within cells. This technology enables targeted treatment of various disease states, including cancer, by focusing on cellular motor proteins. Through its research and development efforts, Myosin Therapeutics aims to address critical challenges in disease management and improve patient outcomes.

TippingPoint Biosciences is focused on developing innovative therapeutics that address diseases caused by defects in DNA packaging, with an emphasis on conditions such as cancer and neurodegenerative disorders. Utilizing a specialized drug discovery platform, the company aims to identify new treatment options that specifically target unique genome packaging states associated with various diseases. This approach not only facilitates the treatment of cancer but also holds potential for advancing stem cell therapies by correcting dysfunctional genome packaging. Through its research and development efforts, TippingPoint Biosciences seeks to provide effective solutions for complex medical challenges.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, that specializes in developing device-based therapies for neurodegenerative diseases. The company focuses on the delivery and monitoring of cerebrospinal fluid (CSF) and employs a proprietary therapeutic platform designed to remove toxic proteins from the CSF. EnClear's initial products are aimed at enhancing the quality of life for patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, EnClear Therapies is dedicated to advancing treatments that can halt disease progression and extend patient lives.

MimiVax, LLC is a clinical-stage biotechnology company based in Buffalo, New York, that specializes in developing immunotherapeutic vaccines and targeted therapies for cancer treatment. Founded in 2011, the company focuses on harnessing survivin-targeting technology to create vaccines that address a cell-survival protein commonly found in many cancers. Its lead product, SurVaxM, is a peptide mimic immunotherapeutic vaccine designed to control tumor growth and prevent recurrence, thereby improving patient survival rates. Through its innovative approaches, MimiVax aims to provide effective treatment options for cancer patients by disrupting the mechanisms that allow tumors to thrive.

Modifi Biosciences specializes in direct DNA modification and the development of innovative cancer therapeutics. The company focuses on a unique strategy that involves altering tumor DNA to make cancer cells irreparable, while ensuring that healthy cells remain unharmed. This approach allows researchers to challenge and advance traditional methods of oncology drug development, potentially leading to more effective treatments for a variety of cancers. By exploiting DNA defects found in cancer cells, Modifi Biosciences aims to contribute significantly to the field of cancer research and therapy.

Kiyatec, LLC is a biotechnology company specializing in the development of advanced 3D cell-based assays aimed at enhancing preclinical drug discovery and clinical therapy applications. Founded in 2005 and based in Greenville, South Carolina, Kiyatec employs its proprietary 3DKUBE technology platform to create functional 3D models using patients' own living tumor cells. This innovative approach allows for the evaluation of various cancer therapies, providing insights into drug toxicity and efficacy before clinical trials. The company offers a range of services, including drug response profiling, predictions of patient responses to therapies, and cell-based assays for oncologists. Additionally, Kiyatec collaborates with biopharma clients on standard and custom assays and conducts research funded by the National Cancer Institute to develop 3D cell culture models for several types of cancer, such as breast cancer, glioblastoma, and lung cancer. By modeling complex human biology and simulating in vivo conditions, Kiyatec aims to improve treatment selection for cancer patients and support the development of medical devices and therapeutic drugs.

AiM Medical Robotics is a company focused on developing an innovative robotic system designed for neurosurgical procedures. This unique system is MRI compatible, allowing patients to receive treatment while inside the MRI scanner, which provides physicians with real-time imaging feedback to enhance surgical outcomes. The robotic platform integrates surgical planning with MR functional robotics, ensuring precise trajectory guidance during procedures. AiM Medical Robotics aims to assist in the treatment of various conditions, including Parkinson's disease, epilepsy, tremors, and brain cancer, ultimately improving the quality of care for patients undergoing neurosurgery for functional brain disorders.

Agrivida, Inc. is a biotechnology company specializing in animal health and nutrition through the development of innovative feed additives for poultry, swine, dairy and beef cattle, and aquaculture. Founded in 2003 and based in Four Seasons, Missouri, Agrivida utilizes its proprietary GRAINZYME technology to produce enzymes directly within corn kernels, offering a natural and effective method to enhance animal diets. This platform enables the integration of beneficial enzymes such as phytase and glucanase, which improve nutritional efficiency and reduce the environmental impact of livestock production. Agrivida's solutions aim to promote healthier food production while delivering economic benefits to its clients in the agricultural sector.

Alpheus Medical specializes in innovative treatments for solid body cancers, focusing on a sonodynamic therapy platform. The company has developed a non-invasive drug-device combination specifically designed for the outpatient treatment of recurrent glioblastoma multiforme, an aggressive form of brain cancer. Utilizing photodynamic therapy, Alpheus Medical's surgical device delivers light to target cancer cells that have been treated with a photosensitizer, allowing patients to receive effective treatment while avoiding the need for invasive brain surgery. This approach underscores the company's commitment to improving patient outcomes through advanced medical technologies.